33 related articles for article (PubMed ID: 38326047)
1. BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study.
Kalashnikova E; Isupova E; Gaidar E; Sorokina L; Kaneva M; Masalova V; Dubko M; Kornishina T; Lubimova N; Kuchinskaya E; Chikova I; Raupov R; Kalashnikova O; Kostik M
World J Clin Pediatr; 2024 Mar; 13(1):89049. PubMed ID: 38596443
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement.
Cheng J; Peng Y; Wu Q; Wu Q; He J; Yuan G
Clin Rheumatol; 2024 Jul; 43(7):2229-2236. PubMed ID: 38767710
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
Pirone C; Mendoza-Pinto C; van der Windt DA; Parker B; O Sullivan M; Bruce IN
Semin Arthritis Rheum; 2017 Dec; 47(3):384-396. PubMed ID: 28602359
[TBL] [Abstract][Full Text] [Related]
4. Description of therapeutic strategies in severe systemic lupus erythematosus-associated immune thrombocytopenia: a retrospective cohort study of response and relapse.
Cimé-Aké E; Barrera-Vargas A; Demichelis-Gómez R; Ramírez-Alemón M; Rull-Gabayet M
Clin Rheumatol; 2024 Jun; ():. PubMed ID: 38916764
[TBL] [Abstract][Full Text] [Related]
5. Rapid and Remarkable Response to Rituximab in a Case of Lupus Enteritis: Challenging the Norm.
Hussein AH; Altamimi BL
Mediterr J Rheumatol; 2024 Mar; 35(1):187-191. PubMed ID: 38855032
[TBL] [Abstract][Full Text] [Related]
6. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
Jovancevic B; Lindholm C; Pullerits R
Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus.
Ilizaliturri-Guerra O; Uriarte-Botello R; Pineda-Sic RÁ; Serna-Peña G; Garza-Elizondo MA; Galarza-Delgado DÁ; Leal-Bramasco AS; Elizondo-Solís CV; Santoyo-Fexas L; Villarreal-Alarcón MÁ
Rheumatol Int; 2020 Oct; 40(10):1717-1724. PubMed ID: 32797277
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of rituximab therapy for 10 patients suffering from systemic lupus erythematosus with intestinal involvement].
Zhao YR; Zhao Z; Zhang J; Li KP; Yang JS; Sun F; Liao SM; Zhang JL; Huang F; Zhu J
Zhonghua Nei Ke Za Zhi; 2024 Feb; 63(2):198-202. PubMed ID: 38326047
[TBL] [Abstract][Full Text] [Related]
9. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.
Gómez VJ; Carrión-Barberá I; Salman Monte TC; Acosta A; Torrente-Segarra V; Monfort J
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):391-395. PubMed ID: 30522941
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
13. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
